GPI stock
GPI.MIMILGPI S.p.A., HealthcareISIN IT0005221517
44Score 44 out of 100, Weak
Price and trend
59 / 100
Price history
+1.2% in one yearThe chart shows daily closes over 11 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 0.5% below it.
Since April 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 50).
The price is 19% below its 52-week high. Largest decline in 11 years: 61% (June 2017 to March 2020).
Chart figures for advanced users
- SMA 50$16.29
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$16.82
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)50
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$14.80
- The lowest closing price of the last twelve months.
- Resistance$20.54
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- GPI S.p.A. belongs to the Medical (Healthcare Information Services) industry (Italy) and, with a market value of $483.45M, is number 23 of 25 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $590.01M (up 6.7% year on year) and earnings of $18.02M (down 84.4%).
- For fiscal 2026, analysts expect on average revenue of $641.64M (up 8.8%) and adjusted earnings per share of $1.09.
Show more
- MEQIRI Score 44 out of 100 (Weak): rank 484 of 714 in Healthcare, median 53.
- The P/E is 26.5 (Medical (Healthcare Information Services) median 43, own median of recent years 23.7).
- Our model puts fair value at $16.04, with the price 4% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Analysts expect strong earnings growthUp 27.8% a year through 2028 (estimates from 3 analysts).
- Consistently profitableProfit in all 10 fiscal years from 2016 to 2025.
- High dividend yieldDividend yield 4.02%, Healthcare sector median 1.38%.
Weaknesses
- DilutionShare count up 83% since 2020.Capital allocation 25
- Interest barely coveredOperating profit covers interest only 1.2 times.Stability 46
- High debtDebt 1.85 times equity (latest quarter), Medical (Healthcare Information Services) median 0.34.Stability 46
The score is held back by profitability and capital allocation.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 42 to 44.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
What lowers it
- calm price action
Valuation
Valuation signal
Fairly valuedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $11.46 and expensive above $26.73 (uncertainty high, one part of the fair value is more than twice the other).
The two parts of the fair value come to $4.92 (cash-flow model) and $27.15 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 16.7%. At 17.7% the fair value would be $15.85, at 15.7% it would be $16.26.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (43).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue rose 1.9% on the twelve months before. Revenue has grown strongly since 2013, at around 20% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 14%, operating 6%, net 3%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 30 Mar 2027in 138 days
- Last reported
- 29 Sep 2026EPS reported $0.16
Analyst estimates
- Earnings per share
- $1.09−9.3%
- Revenue
- $641.64M−4.2%
- Earnings per share
- $1.19−3.6%
- Revenue
- $670.51M−5.5%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at GPI
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 44
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Healthcare Information Services)
The next larger and next smaller companies by market value
- PhreesiaPHR $795.13M55
- SOPHiA GENETICSSOPH $635.9M47
- RaySearch LaboratoriesRAY-B.ST $587.54M66
- NRC HealthNRC $570.01M59
- Evolent HealthEVH $561.28M45
- CarlsmedCARL $507.83M46
- ClaritevCTEV $478.09M42
- Surgical Science SwedenSUS.ST $320.34M66
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = €0.8987)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 24 Apr 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.